Senseonics Holdings, Inc.

We are a medical technology company focused on developing and selling long-term, implantable continuous glucose monitoring (CGM) systems. Our Eversense implantable CGM system, which includes Eversense E3 and Eversense 365, is designed to continuously and accurately measure glucose levels in people with diabetes. The system uses an under-the-skin sensor, a removable and rechargeable smart transmitter, and a mobile app for real-time monitoring. Eversense 365 can monitor glucose for up to twelve months, and Eversense E3 for six months, significantly longer than the seven to 15 days of non-implantable CGM systems. In September 2024, the 365-day extended life Eversense E3 CGM system received FDA approval, and we began commercializing Eversense 365 in the fourth quarter of 2024 through Ascensia Diabetes Care Holdings AG. In January 2026, we assumed full commercial responsibility for Eversense 365 in the United States, marketing and distributing the product with our own sales force. In June 2022, we affixed the CE Mark to the Eversense E3 CGM system, and Ascensia began commercialization in select European markets during the third quarter of 2022. In January 2026, the Company obtained CE Mark approval for Eversense 365. Before the current Eversense systems, we sold Eversense systems that measured glucose for up to 180 days in the United States, and prior to that, 90 days in both the United States and select European markets. In September 2017, we affixed the CE Mark to the Eversense XL CGM system for sale in select markets in Europe and the Middle East. In June 2018, we obtained FDA approval for the 90-day Eversense CGM system for distribution throughout the United States. In June 2019, we received FDA approval for the non-adjunctive indication (dosing claim) for the 90-day Eversense system.